Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4567208 | 0.90 | CYP19A1 (0.33) | CYP19A1PRKCA | |
| SCHEMBL20299549 | 0.89 | CYP19A1 (0.36) | CYP19A1PRKCAMMP1MMP2MMP3 | |
| SCHEMBL4567207 | 0.89 | CYP19A1 (0.36) | CYP19A1PRKCAMMP1MMP2MMP3 | |
| SCHEMBL19899224 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL13147621 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL195816 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL22205226 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL22205224 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL21974553 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 | |
| SCHEMBL16053327 | 0.89 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030376-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | Cerecin Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9175345-B2 | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function | ACCERA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140256808-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8748400-B2 | Use of ketogenic compounds for treatment of age-associated memory impairment | ACCERA, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120122978-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110243885-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | ACCERA, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243885-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | BCKDK, HSD17B12, HSD17B10 | CYP19A1 652/4885PRKCA 491/4885MMP1 4593/4885 |
| US-20140256808-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | CYP19A1 2006/4885PRKCA 859/4885MMP1 3073/4885 |
| US-20160030376-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | BCKDK, HSD17B12, HSD17B10 | CYP19A1 652/4885PRKCA 491/4885MMP1 4593/4885 |
| US-20120122978-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | CYP19A1 2006/4885PRKCA 859/4885MMP1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.